GLAXF News and Press, GlaxoSmithKline Plc From 11/29/23

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

2023-11-29 12:33:02 ET GSK plc (GSK) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 07:30 AM ET Company Participants Jeff McLaughlin - Director, Investor Relations Philip Dormitzer - SVP and Global Head, Vaccines R&D and Infectious Disease Resear...

2023-11-10 14:23:48 ET Summary Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients...

2023-11-07 17:07:59 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-01 14:10:30 ET GSK plc (GSK) Q3 2023 Earnings Conference Call November 01, 2023, 08:00 AM ET Company Participants Nick Stone - Head of Investor Relations Emma Walmsley - Chief Executive Officer Tony Wood - Chief Scientific Officer Luke Miels - Chief C...

2023-10-31 15:25:10 ET Summary ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck, may be interested in ImmunoGen. ImmunoGen has...

2023-10-28 08:35:57 ET Summary GSK's stock price has dropped by 6.7% since July, but still outperformed the S&P 500 and the healthcare sector. This could change, as the company's Q3 2023 earnings are expected to show good financial performance, with double-digit growth expecte...

2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...

2023-10-16 18:25:10 ET Summary Vaxcyte, Inc. is making substantial progress with its vaccine candidate VAX-24 for the prevention of invasive pneumococcal disease as evidenced by trial data. Obtained positive immunogenicity data from its phase 2 study in adults for prevention of IP...

2023-10-16 12:27:11 ET Summary Sartorius is facing challenging business conditions due to destocking and delayed customer investment. The company's ability to maintain high levels of sustained growth is a concern due to increasing competition and financing costs. We downgrade ...